NCCN Guidelines® Insights - Non-Small Cell Lung Cancer, Version 6.2015
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Non-Small Cell Lung Cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non-Small Cell Lung Cancer
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician